The Study
Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans
This study watched what happened to people and mice who took a weight-loss medicine and noticed that their muscles didn’t shrink as much as their fat. But because we don’t know if everyone was randomly assigned to take it or not, we can’t say the medicine definitely caused the changes — it might just be coincidence.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
These drugs help you lose mostly fat, not muscle—even though you lose a little muscle, you become stronger relative to your weight and can run better.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 557 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes—people lose fat faster than muscle, so they get stronger and more mobile even if their muscles shrink a little.
- 2In mice and humans: fat loss 70–73%, muscle loss only 5–13%.
- 3Muscle strength stayed the same relative to body weight.
- 4Mice on the drug ran as far as lean mice.
- 5Liver shrank more than muscle.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cell Reports Medicine
Year
2026
Authors
H. Langer, Natalie K. Gilmore, C. M. Hayden, Julien Roux, Bruno Bariohay, Thaïs Rouquet, Manar Awada, Julie Marcotorchino, Lorrine Bournot, Elizabeth Nunn, Paul M. Titchenell, D. Liśkiewicz, Timo D. Müller, Oluwaseun Anyiam, Philip J. Atherton, Iskandar Idris, A. Hentschel, Andreas Roos, N. Haritonow, Kristina Norman, U. Müller-Werdan, Keith Baar
Related Content
Claims (6)
GLP-1 receptor agonists trigger changes in the body that occur even when weight loss is accounted for, suggesting these drugs have effects beyond reducing body weight.
In obese mice, using GLP-1 receptor agonists to lose weight does not cause more muscle loss during periods of inactivity than reducing calorie intake alone.
In obese mice, GLP-1 receptor agonists help maintain muscle function during weight loss by causing more fat to be lost than muscle, so the mice can run as well as lean mice even though their muscles get smaller.
In obese individuals with type 2 diabetes and in obese mice, GLP-1 receptor agonists cause weight loss primarily from fat tissue, while muscle mass is largely preserved. This results in a higher proportion of muscle relative to total body weight and maintained muscle strength, even though the total amount of muscle decreases slightly.
When people lose the same amount of weight through either GLP-1 receptor agonists or calorie restriction, the drugs cause different changes in muscle proteins related to energy production and protein breakdown compared to dieting alone.
In obese mice undergoing weight loss, drugs that activate GLP-1 receptors cause a larger decrease in liver size compared to muscle size, suggesting these drugs primarily affect how the liver processes energy.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.